We are dedicated to translating state-of-the art science into novel medicines for the treatment of diseases that pose great challenges to patients, their physicians and their families. Our strength derives from our focus on a small family of diseases, the skills and experience of our team and the commitment of our investors.
Basic biological discoveries that illuminate clinical matters inspire us – particularly the prospect of taking one of those insights and translating it into a treatment that is clinically meaningful. In this era, the genomic age of medical science, the underlying biochemical aberrations of many conditions have been revealed but patients have not yet been the beneficiaries.
Hematologic diseases that result in bone marrow failure or leukemia are common but extremely complex. Although some, like myelodysplastic syndrome (MDS), can manifest as anemias manageable with transfusions, more often they are life-threatening and difficult to treat, such as acute myelogenous leukemia (AML). Although standard chemotherapy or bone marrow transplants help some, the majority of patients with AML are not cured.
Our name, Imago, invokes the final and fully developed stage of an insect after its metamorphosis. In this process of growth and development, the imago is often referred to as the adult stage, as it completes its transformation and, for a butterfly, takes flight. The final stage of medical research is when new medicines prove their worth in clinical studies.